NAYA Biosciences Reports $17.4 Million Net Loss Amid Strategic Changes and Impairment Loss

NAYA Biosciences, Inc. reported a significant financial downturn in its latest quarterly filing, revealing a net loss of approximately $17.4 million for the three months ended March 31, 2025, compared to a loss of $1.6 million during the same period in 2024. The company's total revenue remained relatively stable at $1.6 million, a slight increase from $1.58 million in the previous year. However, the substantial rise in operating expenses, which surged to $18.7 million from $3.1 million, was primarily driven by a $14.6 million impairment loss related to the acquisition of NAYA Therapeutics, Inc. This impairment was attributed to a decline in the company's stock price.

The company has undergone significant strategic changes, including the acquisition of NAYA Therapeutics in October 2024, which it now plans to divest to refocus on its core fertility business. This decision follows a lack of shareholder support for key elements of the NAYA transaction. NAYA Therapeutics, which specializes in oncology and autoimmune technologies, will continue to operate independently, while NAYA Biosciences will concentrate on expanding its fertility services, including the operation of INVO Centers and the distribution of its proprietary INVOcell device.

Operationally, NAYA Biosciences has two operational INVO Centers and one IVF clinic in the United States. The company aims to grow its clinic network and has identified several profitable IVF practices for potential acquisition. As of March 31, 2025, the company reported a negative working capital of approximately $17.1 million, reflecting ongoing liquidity challenges. The total assets decreased to $31.7 million from $46.4 million at the end of 2024, primarily due to the impairment of goodwill and other intangible assets.

Looking ahead, NAYA Biosciences anticipates that its fertility operations will improve as it implements new operational procedures and continues to pursue additional acquisitions. The company expects to benefit from the growing demand for assisted reproductive technology (ART) services, driven by increasing infertility rates and a larger underserved patient population. However, the company acknowledges that it will need to secure additional funding to meet its liquidity needs and execute its business strategy effectively. The outlook remains cautious, with the company emphasizing the importance of raising capital through debt and equity financing to support its operations and growth initiatives.